Switzerland's Speedel has initiated a Phase III trial of its experimental SPP 301 for diabetic kidney disease. Company officials touted the move as a milestone of "major strategic importance," noting that it's the first Phase III trial that Speedel has launched alone. SPP 100 is in Phase III -- with Novartis as a partner -- for hypertension. Speedel believes that both drugs have blockbuster potential.
- read this story from AFX for more